Novo Nordisk (NVO) Suffers a Larger Drop Than the General Market: Key Insights

Stock Performance - Novo Nordisk closed at $83 34, marking a -1 99% move from the previous day, lagging the S&P 500's daily loss of 1 11% [1] - Shares of the company witnessed a loss of 23 45% over the previous month, trailing the Medical sector's loss of 6 22% and the S&P 500's loss of 1 7% [1] Earnings and Revenue Projections - The company's upcoming EPS is projected at$ 0 85, signifying a 19 72% increase compared to the same quarter of the previous year [2] - Revenue is expected to be $11 34 billion, up 19 23% from the prior-year quarter [2] Analyst Estimates and Revisions - Positive revisions in analyst estimates convey confidence in the company's business performance and profit potential [3] - The Zacks Consensus EPS estimate has witnessed a 3 06% decrease over the last 30 days [5] - Novo Nordisk currently carries a Zacks Rank of 4 (Sell) [5] Valuation Metrics - Novo Nordisk is trading with a Forward P/E ratio of 21 89, a premium compared to the industry average of 12 34 [6] - The company has a PEG ratio of 0 91, lower than the industry average of 1 26 [6] Industry Overview - The Large Cap Pharmaceuticals industry is part of the Medical sector and carries a Zacks Industry Rank of 191, placing it within the bottom 24% of over 250 industries [7] - The top 50% rated industries outperform the bottom half by a factor of 2 to 1 [7]